Consensus Denali Therapeutics Inc. Sao Paulo

Stocks

D2NL34

BRD2NLBDR008

Biotechnology & Medical Research

Market Closed - Sao Paulo 14:04:39 2026-07-13 EDT			5-day change	1st Jan Change
27.06 ^BRL	-1.31%		-.--%	+25.57%

08-25	B. Riley Adjusts Denali Therapeutics Price Target to $35 From $30, Maintains Buy Rating	MT
08-24	FDA places clinical hold on Regenxbio's gene therapy for Hunter Syndrome	RE

Evolution of the Average Target: Denali Therapeutics Inc.

Evolution of the Target Price: Denali Therapeutics Inc.

Changes in Analyst Recommendations: Denali Therapeutics Inc.

fbd685bc34f5926.Tiun-6di0zV-bGK9wdL9OLaPwegX6yRq6Obhxt8ODIE.fE-Uw_ARugIyICr5jpG4dtHMmZBU2WMB0bDQsIhafLY8Sv_L3ji6Rx1dCQ~e0599aa3034ee6d1956e04fd9d373345

Analysts' recommendations: Denali Therapeutics Inc.

08-25	B. Riley Adjusts Denali Therapeutics Price Target to $35 From $30, Maintains Buy Rating	MT
08-07	UBS Adjusts Price Target on Denali Therapeutics to $34 From $25, Maintains Buy Rating	MT
08-07	Wedbush Adjusts PT on Denali Therapeutics to $27 From $26, Maintains Outperform Rating	MT
07-16	Deutsche Bank Adjusts Price Target on Denali Therapeutics to $35 From $31, Maintains Buy Rating	MT
07-13	Wedbush Raises Price Target on Denali Therapeutics to $26 From $20, Keeps Outperform Rating	MT
05-26	Denali Therapeutics' Focus Shifts to Other Pipeline Assets After Phase 2b Study Failure, Morgan Stanley Says	MT
05-22	Morgan Stanley Cuts Price Target on Denali Therapeutics to $35 From $40, Keeps Overweight Rating	MT
05-22	Wedbush Cuts Price Target on Denali Therapeutics to $20 From $23, Keeps Outperform Rating	MT
05-22	Deutsche Bank Adjusts Denali Therapeutics Price Target to $31 From $35, Maintains Buy Rating	MT
05-14	Morgan Stanley Trims Price Target on Denali Therapeutics to $40 From $42, Keeps Overweight Rating	MT
05-11	Denali Therapeutics Seeing Encouraging Signals From Avlayah Launch, Oppenheimer Says	MT
05-08	Wedbush Adjusts Denali Therapeutics Price Target to $23 From $25, Maintains Outperform Rating	MT
04-21	Wedbush Cuts Price Target on Denali Therapeutics to $25 From $30, Keeps Outperform Rating	MT
03-26	Deutsche Bank Raises Price Target on Denali Therapeutics to $35 From $26, Keeps Buy Rating	MT
03-26	Morgan Stanley Lifts Price Target on Denali Therapeutics to $42 From $40, Keeps Overweight Rating	MT
01-07	UBS Adjusts Price Target on Denali Therapeutics to $25 From $24, Maintains Buy Rating	MT
12-11	Wedbush Trims Price Target on Denali Therapeutics to $30 From $31, Keeps Outperform Rating	MT
12-05	Wedbush Adjusts Denali Therapeutics Price Target to $31 From $30, Maintains Outperform Rating	MT
11-17	Centessa Pharmaceuticals, CG Oncology Drive Q3 Biotech Momentum, Morgan Stanley Says	MT
11-17	Morgan Stanley Raises Price Target on Denali Therapeutics to $32 From $30, Keeps Overweight Rating	MT
25-10-13	Denali's FDA Approval for Hunter Syndrome's Drug Candidate Extended	MT
25-10-13	Denali Therapeutics announces FDA review extension of BLA for Tividenofusp alfa	RE
25-10-13	Denali Therapeutics Announces FDA Review Extension of BLA for Tividenofusp Alfa for the Treatment of MPS II (Hunter Syndrome)	CI
25-05-08	B. Riley Adjusts Denali Therapeutics Price Target to $30 From $35, Maintains Buy Rating	MT
25-05-08	Deutsche Bank Adjusts Denali Therapeutics Price Target to $28 From $29, Maintains Buy Rating	MT

More recommendations

Bio Therapeutic Drugs

	Add to a list 0 selected To use this feature you must be a member Log in Sign up	Consensus	Analysts' recommendations evolution (4 months)	Financial estimates divergence	Analysts' Target price divergence	Objective/dr gap
	WUXI APPTEC CO., LTD.					+18.83%
	ARGENX SE					+12.23%
	WUXI BIOLOGICS (CAYMAN) INC.					+16.45%
	INSMED INCORPORATED					+64.33%
	BIONTECH SE					+18.32%
	PHARMAESSENTIA CORPORATION					-3.81%
	GENMAB A/S					+14.38%
	SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.					+24.38%
	EXELIXIS, INC.					-1.74%
	Average					+18.15%
	Weighted average by Cap.					+18.91%